Region Midtjylland
- Address
- lock Available on a paid plan
Cardiovascular Clinical Research
The Oncology Department at Region Midtjylland conducts studies focused on atherosclerotic cardiovascular disease and the prevention of recurrent ischemic events. Trials aim to test new oral agents that could lower the risk of major adverse cardiovascular events and improve safety for patients already on antiplatelet therapy.
- Evaluation of MK-0616 to reduce major adverse cardiovascular events in high‑risk individuals
- Testing the oral FXIa inhibitor asundexian for stroke prevention after acute non‑cardioembolic ischemic stroke or high‑risk TIA
- Safety assessment of major bleeding rates with asundexian compared to placebo in patients on antiplatelet therapy
With 64 investigators, the site supports robust cardiovascular research while maintaining patient‑centered care.
Oncology and Sarcoma Research
In the field of neoplasms, the center evaluates innovative treatment strategies for aggressive retroperitoneal sarcomas, including high‑risk de‑differentiated liposarcoma and leiomyosarcoma. The goal is to determine whether adding chemotherapy before curative‑intent surgery can improve disease‑free survival.
- Preoperative chemotherapy for high‑risk de‑differentiated liposarcoma and its impact on surgical outcomes
- Assessment of disease‑free survival benefits for patients with retroperitoneal leiomyosarcoma
- Comparative analysis of surgery alone versus surgery combined with neoadjuvant chemotherapy
The program reflects the department’s commitment to advancing cancer care through multidisciplinary collaboration.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 33 therapeutic areas and 15 of 514 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 474 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 80 by active trials.
- 1Region Midtjylland39active
lock +79 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Midtjylland55trials
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Midtjylland
lock Showing 1 of 313 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 514 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 17 | Unknown | 2013-10-18 | 2025-09-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.